Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation-Reference-Cited by-同舟云学术

Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation

Published:2000-06 Issue:12 Volume:25 Page:1219-1222
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Copelan EA,Penza SL,Elder PJ,Ezzone SA,Scholl MD,Bechtel TP,Belt PS,Avalos BR

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/1702432.pdf

Reference28 articles.

1. Cheson BD . The myelodysplastic syndromes: current approaches to therapy Ann Intern Med 1990 112: 932–941

2. Anderson JE, Appelbaum FR, Fisher LD et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome Blood 1993 82: 677–681

3. Anderson JE, Appelbaum FR, Storb R . An update on allogeneic marrow transplantation for myelodysplastic syndrome Leuk Lymphoma 1995 17: 95–99

4. Anderson JE, Appelbaum FR, Schoch G et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors Blood 1996 87: 51–58

5. Ratanatharathorn V, Karanes C, Uberti J et al. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes Blood 1993 81: 2194–2199

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pyrrolizidine Alkaloids: Potential Role in the Etiology of Cancers, Pulmonary Hypertension, Congenital Anomalies, and Liver Disease;Chemical Research in Toxicology;2014-12-26

2. Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy;Stem Cells and Cloning: Advances and Applications;2014-12

3. Response to pretransplant hypomethylating agents influences the outcome of allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndromes;European Journal of Haematology;2013-01-07

4. Allogeneic Hematopoietic Stem-Cell Transplantation for Patients 50 Years or Older With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia;Journal of Clinical Oncology;2010-01-20

5. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML;Bone Marrow Transplantation;2009-09-21